Volume 23, Number 6—June 2017
Domestic Pig Unlikely Reservoir for MERS-CoV
Highlight and copy the desired format.
|EID||de Wit E, Feldmann F, Horne E, Martellaro C, Haddock E, Bushmaker T, et al. Domestic Pig Unlikely Reservoir for MERS-CoV. Emerg Infect Dis. 2017;23(6):985-988. https://dx.doi.org/10.3201/eid2306.170096|
|AMA||de Wit E, Feldmann F, Horne E, et al. Domestic Pig Unlikely Reservoir for MERS-CoV. Emerging Infectious Diseases. 2017;23(6):985-988. doi:10.3201/eid2306.170096.|
|APA||de Wit, E., Feldmann, F., Horne, E., Martellaro, C., Haddock, E., Bushmaker, T....Feldmann, H. (2017). Domestic Pig Unlikely Reservoir for MERS-CoV. Emerging Infectious Diseases, 23(6), 985-988. https://dx.doi.org/10.3201/eid2306.170096.|
We tested the suitability of the domestic pig as a model for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Inoculation did not cause disease, but a low level of virus replication, shedding, and seroconversion were observed. Pigs do not recapitulate human MERS-CoV and are unlikely to constitute a reservoir in nature.
As of March 10, 2017, a total of 1,917 cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection and 684 fatalities have occurred (1). Despite the relatively large number of cases, little is known about the disease pathology of MERS in humans (2). Our current understanding of the pathogenesis of MERS-CoV is therefore mostly based on data derived from studies in animal models. Although the first animal model used to study MERS-CoV pathogenesis and test potential countermeasures became available shortly after the discovery of MERS-CoV (3), all the animal models that have been developed so far have drawbacks (4). Because of the host restriction conferred by the binding of the MERS-CoV spike protein to its receptor, dipeptidyl peptidase 4 (DPP4), small animal models that are routinely used to conduct infectious disease research are not naturally susceptible to MERS-CoV infection. Although human DPP4-transgenic mouse models have been developed, these do not completely recapitulate the disease pathology observed in humans. Nonhuman primate models recapitulate mild and moderate human disease pathology; however, practical and ethical constraints limit work with these models.
The domestic pig (Sus domesticus) is used in infectious disease research because of similarities between human and pig anatomy, genetics, and physiology (5). MERS-CoV was previously shown to replicate in porcine kidney cells, albeit less efficiently than in human kidney cells (6). In an effort to develop a MERS-CoV animal model that recapitulates human disease better than small animal models without the constraints associated with nonhuman primate studies, we explored the possibility of using the domestic pig as an animal model of MERS-CoV infection.
Comparison of the DPP4 nucleotide sequences of humans, dromedary camels, and domestic pigs showed that the porcine DPP4 is identical to the dromedary camel DPP4 at the 14 aa positions that have been shown to determine species tropism (Table) (8,9). We investigated whether DPP4 is expressed in the pig respiratory tract by performing immunohistochemical staining on the nasal mucosa and lung tissue obtained from healthy pigs using an antibody against DPP4 (mouse monoclonal anti-DPP4 [CD26], clone OTI11D7, 1:2,500; Origene Technologies, Inc., Rockville, MD, USA). DPP4 expression was not observed in the nasal mucosa of healthy domestic pigs (Figure 1, panel A); in the lungs, abundant DPP4 expression was observed in type I and type II pneumocytes and submucosal glands (Figure 1, panel B), suggesting MERS-CoV infection would be supported.
We inoculated 2 groups of four 4–5-week-old farm pigs (Yorkshire cross; S&S Farms, Ramona, CA, USA) intranasally (1 mL/nostril) and intratracheally (5 mL) with a total dose of 106 tissue culture infectious dose 50 (TCID50) of the hCoV-EMC/2012 isolate of MERS-CoV. A group of 3 control pigs was mock inoculated with Dulbecco’s modified Eagle medium (DMEM); these pigs were housed in a separate room from the MERS-CoV–inoculated pigs to prevent cross-contamination. Animal experiments were approved by the Institutional Animal Care and Use Committee of the Rocky Mountain Laboratories and conducted by certified staff in an Association for Assessment and Accreditation of Laboratory Animal Care International–accredited facility according to the institution’s guidelines for animal use; staff followed the guidelines and basic principles in the US Public Health Service Policy on Humane Care and Use of Laboratory Animals and the Guide for the Care and Use of Laboratory Animals.
After inoculation with MERS-CoV, none of the pigs showed clinical signs of disease, such as increased body temperature or increased respiration, and bodyweight gain was similar between MERS-CoV–inoculated and mock-inoculated pigs (Figure 2, panel A). We collected nose and throat swabs during clinical exams and analyzed them for the presence of viral RNA by quantitative reverse transcription PCR (qRT-PCR) as described (10). Shedding of viral RNA from the nose and the throat increased from 1 day postinoculation (dpi) to 3 dpi in all MERS-CoV–inoculated animals, a sign that active replication occurred; shedding was higher in the nose than in the throat (Figure 2, panel B). After 3 dpi, shedding of viral RNA decreased; all nose swabs were negative by 11 dpi and all throat swabs by 7 dpi.
We attempted virus propagation by inoculating VeroE6 cells with the media used to resuspend nasal and throat swab particulates and checking for the development of MERS-CoV cytopathic effect. Infectious MERS-CoV was not recovered at any time postinoculation from any swab sample.
On 4 and 11 dpi, we euthanized 4 MERS-CoV–inoculated pigs and collected their tissues for virologic and histologic analysis. Viral RNA could be detected by qRT-PCR in >1 respiratory tract tissue samples of all 4 MERS-CoV–inoculated pigs. However, viral loads were low; infectious MERS-CoV could not be isolated from any tissues positive by qRT-PCR, and the distribution of viral RNA among tissues was inconsistent from pig to pig (Figure 2 panel C). By 11 dpi, viral RNA could only be detected in the bronchial lymph node of 1 MERS-CoV–inoculated pig (Figure 2 panel C); all the tissues examined from other MERS-CoV–inoculated pigs were negative by this time. Viral RNA could not be detected in any of the extrarespiratory tissues tested, such as heart, liver, spleen, kidney, adrenal gland, duodenum, ileum, transverse colon, or urinary bladder, on 4 dpi or 11 dpi (data not shown). Histologic analysis did not reveal any lesions consistent with MERS-CoV infection in any of the collected tissues, including those of the respiratory tract. We performed immunohistochemical staining with an antibody specific for MERS-CoV on tonsil, trachea, bronchial lymph node, and right and left lower lung lobe of all pigs, as well as other tissues that tested positive for viral RNA by qRT-PCR. MERS-CoV antigen could not be detected in any of these tissues.
Serum samples collected on the day of euthanasia were tested for the presence of antibodies against MERS-CoV spike protein 1 (S1) by ELISA. By 11 dpi, antibodies directed against MERS-CoV S1 could be detected in all 4 pigs (Figure 2, panel D).
Recently, Vergara-Alert et al. showed MERS-CoV shedding in pigs inoculated with 107 TCID50 of MERS-CoV and suggested that pigs could play a role as a reservoir for the circulation of MERS-CoV (12). In our hands, pigs inoculated with a 10-fold lower infectious dose of MERS-CoV were also successfully infected, but the low amount of virus replication in and shedding from the respiratory tract implies that the pig is unlikely to play a profound role as an intermediate host for MERS-CoV in nature.
Taken together, our data indicate that MERS-CoV can infect pigs, leading to a low level of replication in the pig respiratory tract, but does not cause clinical signs of disease. Furthermore, viral shedding from mucosal membranes of the upper respiratory tract was rather limited with no infectious virus measurable at any time postinoculation. Thus, the pig is not a suitable animal disease model for MERS-CoV infection.
Dr. de Wit is a staff scientist in the Disease Modeling and Transmission section of the Laboratory of Virology. Her research interests are in the pathogenesis and transmission of emerging viruses.
The authors thank the Rocky Mountain Veterinary Branch staff for the care and handling of the animals, Anita Mora for help with figure preparation, and Juergen Richt for helpful advice.
This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
- World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV)–Saudi Arabia. Disease outbreak news. 2017 Mar 10 [cited 2017 Mar 15]. http://www.who.int/csr/don/10-march-2017-mers-saudi-arabia/en/
- Ng DL, Al Hosani F, Keating MK, Gerber SI, Jones TL, Metcalfe MG, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol. 2016;186:652–8.
- Munster VJ, de Wit E, Feldmann H. Pneumonia from human coronavirus in a macaque model. N Engl J Med. 2013;368:1560–2.
- Baseler L, de Wit E, Feldmann H. A comparative review of animal models of Middle East respiratory syndrome coronavirus infection. Vet Pathol. 2016;53:521–31.
- Meurens F, Summerfield A, Nauwynck H, Saif L, Gerdts V. The pig: a model for human infectious diseases. Trends Microbiol. 2012;20:50–7.
- Müller MA, Raj VS, Muth D, Meyer B, Kallies S, Smits SL, et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio. 2012;3:e00515-12.
- van Doremalen N, Munster VJ. Animal models of Middle East respiratory syndrome coronavirus infection. Antiviral Res. 2015;122:28–38.
- Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500:227–31.
- Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013;23:986–93.
- Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill. 2012;17:20285.
- de Wit E, Rasmussen AL, Falzarano D, Bushmaker T, Feldmann F, Brining DL, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A. 2013;110:16598–603.
- Vergara-Alert J, van den Brand JM, Widagdo W, Muñoz M V, Raj S, Schipper D, et al. Livestock susceptibility to infection with Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2017;23:232–40.
- Figure 1. Dipeptidyl peptidase (DPP) 4 expression in the domestic pig respiratory tract. Tissues were stained by using a cross-reactive mouse monoclonal antibody against DPP4 (CD26, clone OTI11D7, 1:2,500; Origene Technologies,...
- Figure 2. Propagation of Middle East respiratory syndrome coronavirus (MERS-CoV) in domestic pigs. We inoculated pigs intranasally and intratracheally with 106 tissue culture infectious dose 50 (TCID50) of MERS-CoV isolate hCoV-EMC/2012...
- Table. Comparison of the amino acid residues shown to be essential in binding of Middle East respiratory syndrome coronavirus spike protein to DPP4 of human, dromedary camel, and domestic pig
Please use the form below to submit correspondence to the authors or contact them at the following address:
Heinz Feldmann, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, 903 S 4th St, Hamilton, MT 59840, USA
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: May 16, 2017
- Page last updated: May 16, 2017
- Page last reviewed: May 16, 2017
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)